nivolumab subcutaneous (BMS-986298) / Ono Pharma, BMS  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nivolumab subcutaneous (BMS-986298) / BMS, Ono Pharma
2020-003655-15: A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Étude sur le nivolumab sous-cutané dans le carcinome rénal à cellules claires avancé ou métastatique précédemment traité

Ongoing
3
458
Europe, RoW
Nivolumab Subcutaneous coformulated with excipient rHuPH20, Nivolumab-10 ml vial-COMMERCIAL, BMS-986298-01, BMS-936558, Solution for injection, Concentrate for solution for infusion, Opdivo (100 mg/10 ml)
Bristol-Myers Squibb International Corporation, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation
Metastatic Clear Cell Renal Cell Carcinoma, Kidney Cancer, Diseases [C] - Cancer [C04]
 
 
2021-003208-42: A Pharmacokinetic Study of Nivolumab Administered Subcutaneously vs Intravenous Nivolumab in Participants with Stage III A/B/C/D or Stage IV Melanoma Following Complete Resection Estudio farmacocinético de nivolumab administrado por vía subcutánea en comparación con nivolumab intravenoso en participantes con melanoma en estadio IIIA/B/C/D o estadio IV tras la resección completa

Ongoing
3
379
Europe
Nivolumab Subcutaneous coformulated with excipient rHuPH20, Nivolumab-10 ml vial-COMMERCIAL, BMS-986298-01, BMS-936558, Solution for injection, Concentrate for solution for infusion, Opdivo (100 mg/10 ml)
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Resected Stage IIIA/B/C/D or Stage IV melanoma in an adjuvant setting Melanoma en estadio IIIA/B/C/D o estadio IV tras la resección completa en un entorno adyuvante, Melanoma Stage III or Stage IV Melanoma en estadio III o estadio IV, Diseases [C] - Cancer [C04]
 
 
CheckMate 6GE, NCT05297565 / 2021-003208-42: A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

Completed
3
14
Europe, US, RoW
Nivolumab/rHuPH20, BMS-986298, Nivolumab, BMS-936558, Opdivo
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Melanoma
02/24
02/24
CheckMate 67T, NCT04810078 / 2020-003655-15: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Recruiting
3
632
Europe, US, RoW
Nivolumab and rHuPH20, BMS-986298, Nivolumab, Opdivo, BMS-936558
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Clear Cell Renal Cell Carcinoma
09/25
01/26

Download Options